Sonoma Biosciences, which splits operations between South San Francisco and Seattle, received $40 million in financing to develop cell therapies for autoimmune diseases. Traditionally used for cancer, Sonoma Bio’s therapies instead utilize a patient’s regulatory T cell (Treg) that can target other immune cells, shutting down unwanted immune responses. Ultimately, they are hoping that this cell therapy can be a one-time treatment.
Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer
Share: